Abstract
As the most common form of arthritis, osteoarthritis (OA) is prevalent in the elderly, bringing patients pain and functional limitations of joints. Current medication treatments of OA mainly consist of oral and intra-articular administration. Despite the undeniable advantages over oral administration, the efficacy of intra-articular therapy is still limited by the rapid clearance of drugs. To guarantee the efficacy and avoid frequent injections, rationally designed intra-articular drug delivery systems (DDSs), which may remain in OA joints for a long time and sustainedly release drugs, are clinically in need. In this article, we present a review of the novel intra-articular DDSs for OA treatment reported recently, especially in the last five years. Factors influencing the biocompatibility and efficacy of such systems are also addressed. Moreover, the potential fate of different systems in joints is highlighted. Future innovations in this field may lie in the discovery of effective DMOADs and the development of novel biomaterials as carriers of bioactivity substances.
Keywords: Depot formulation, drug delivery system, intra-articular administration, osteoarthritis (OA), targeted delivery.
Current Drug Targets
Title:Progress in Intra-Articular Drug Delivery Systems for Osteoarthritis
Volume: 15 Issue: 9
Author(s): Xiaoye Yang, Hongliang Du and Guangxi Zhai
Affiliation:
Keywords: Depot formulation, drug delivery system, intra-articular administration, osteoarthritis (OA), targeted delivery.
Abstract: As the most common form of arthritis, osteoarthritis (OA) is prevalent in the elderly, bringing patients pain and functional limitations of joints. Current medication treatments of OA mainly consist of oral and intra-articular administration. Despite the undeniable advantages over oral administration, the efficacy of intra-articular therapy is still limited by the rapid clearance of drugs. To guarantee the efficacy and avoid frequent injections, rationally designed intra-articular drug delivery systems (DDSs), which may remain in OA joints for a long time and sustainedly release drugs, are clinically in need. In this article, we present a review of the novel intra-articular DDSs for OA treatment reported recently, especially in the last five years. Factors influencing the biocompatibility and efficacy of such systems are also addressed. Moreover, the potential fate of different systems in joints is highlighted. Future innovations in this field may lie in the discovery of effective DMOADs and the development of novel biomaterials as carriers of bioactivity substances.
Export Options
About this article
Cite this article as:
Yang Xiaoye, Du Hongliang and Zhai Guangxi, Progress in Intra-Articular Drug Delivery Systems for Osteoarthritis, Current Drug Targets 2014; 15 (9) . https://dx.doi.org/10.2174/1389450115666140804155830
DOI https://dx.doi.org/10.2174/1389450115666140804155830 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Epstein-Barr Virus-associated Gastric Cancer and Potential Mechanisms of Oncogenesis
Current Cancer Drug Targets Genetic Polymorphisms of Human Sulfate Transporters
Current Pharmacogenomics Hepatitis C Virus NS3/4A Protease Inhibitors
Recent Patents on Anti-Infective Drug Discovery A Retrospective Study on <i>Gloriosa superba</i> and Its Main Active Constituents
The Natural Products Journal The Recognition of Abnormal Forms of HLA-B27 by CD4+ T Cells
Current Molecular Medicine Recent Patents on the Treatment of Type 1 Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Chronic Stress and Diabetes Mellitus: Interwoven Pathologies
Current Diabetes Reviews Dry Age-Related Macular Degeneration: Recent Progress of Therapeutic approaches
Current Molecular Pharmacology Profiling the Shear Stress of Atherosclerosis; A Genomic View
Current Genomics Characterization of the Prostaglandin E2 Pathway in a Rat Model of Esophageal Adenocarcinoma
Current Cancer Drug Targets Telomere Maintenance as Therapeutic Target in Embryonal Tumours
Anti-Cancer Agents in Medicinal Chemistry Diabetic CVD – Soluble Epoxide Hydrolase as A Target
Cardiovascular & Hematological Agents in Medicinal Chemistry NMR Spectroscopy and Protein Structure Determination: Applications to Drug Discovery and Development
Current Pharmaceutical Biotechnology Circulating Biochemical Markers of Brain Damage in Infants Complicated by Ischemia Reperfusion Injury
Cardiovascular & Hematological Agents in Medicinal Chemistry Probiotics and the Intestinal Microflora: What Impact on the Immune System, Infections and Aging?
Current Nutrition & Food Science Zn Finger Containing Proteins as Targets for the Control of Viral Infections
Infectious Disorders - Drug Targets DPP4 Inhibitors: Could they be One of the Solutions for COVID-19 Patients with Prediabetes?
Current Reviews in Clinical and Experimental Pharmacology Approaches Used in Immunotherapy for Prostate Cancer
Current Cancer Therapy Reviews Revolutionary Impact of Nanodrug Delivery on Neuroscience
Current Neuropharmacology Molecular Mechanism of a Specific NLRP3 Inhibitor to Alleviate Seizure Severity Induced by Pentylenetetrazole
Current Molecular Pharmacology